Medicare Part D prescription drug plans are explicitly prohibited from covering obesity medications2
Results from the TRIUMPH-4 trial, published in December 2025, showed participants with obesity and knee osteoarthritis taking retatrutide 12mg lost an average of 28.7% of their body weight at 68 weeks
Ethical treatment under GCP not only protects patients but also upholds the integrity of the research, ensuring that participants are respected and treated with care throughout the trial process
Key takeaways: Ozempic and other GLP-1 medications can reduce your appetite, meaning youre less likely to take in large amounts of fiber-rich fluids
High drug levels for the first few days, declining levels toward the end of the week
Fulfillment then goes to a retail pharmacy for FDA-approved brand products, or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide